Bond Prices Lean Higher

Bond Prices Lean Higher

U.S. Treasury prices were mixed but little-changed Thursday with the long bond stalled in negative territory while the remainder of the curve cling to minor gains. Wednesday’s Federal Open Market Committee September meeting minutes chatter over the low-inflation situation has kept the issue on traders’ radars, although there was little sustained reaction to the earlier pop in the core producer price index (PPI) report with data muddied by the hurricanes. […]

Read More ˃
Tech Stocks Close Gap With Financial Sector for Market Lead

Tech Stocks Close Gap With Financial Sector for Market Lead

Technology stocks were ending mostly higher, helping to carry the broader U.S. markets to gains, with shares of tech companies in the S&P 500 rising more than 0.9% in recent trade. In company news, NeoPhotonics (NPTN) fell to a 30-month low on Thursday, sinking to its lowest price since March 2015 at $4.93 a share, after the maker of digital optical receivers and switches said it was beginning an aggressive […]

Read More ˃
Health Care Stocks Pare Nearly All of Thursday Losses

Health Care Stocks Pare Nearly All of Thursday Losses

Most health care stocks largely sat out the advance for stocks, with the NYSE Health Care Index sinking almost 0.1% while shares of health care companies in the S&P 500 were down less than 0.1% as a group. In company news, Valeritas Holdings (VLRX) stumbled Thursday after late Wednesday disclosing plans to sell up to 3.35 million shares of its common stock by Aspire Capital Partners, which late last month […]

Read More ˃
Alliqua BioMedical Effects 1-for-10 Reverse Stock Split

Alliqua BioMedical Effects 1-for-10 Reverse Stock Split

Alliqua BioMedical (ALQA) said Thursday it will effect a reverse stock split of its issued and outstanding common stock at an exchange ratio of 1-for-10, after the close of business on Oct. 5. As a result of the reverse stock split, there will be approximately 4.9 million shares of common stock outstanding. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in […]

Read More ˃
Pfizer Reports FDA Gives Priority Review To Myeloid Leukemia Treatment

Pfizer Reports FDA Gives Priority Review To Myeloid Leukemia Treatment

Pfizer (PFE) and the private Avillion reported Tuesday a supplemental new drug application for bosutinib, a drug to treat certain types of myeloid leukemia, has been accepted for filing and granted priority review by the U.S. Food and Drug Administration (FDA). Pfizer said that if approved, the new application would expand the approved use of bosutinib to include patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukemia. Pfizer […]

Read More ˃